SUBSCRIBE Blog with us: BLOGbiotech

GEN News Highlights

• Email
• Print
• Share
• More GEN News Highlights

Nov 5 2009, 11:16 AM EST

Micromet Axes Alliance with MedImmune Regaining Rights to Clinical-Stage Cancer Drug

GEN News Highlights

Micromet is buying out MedImmune’s option to blinatumomab in North America and is terminating their collaboration, which began in 2003. Micromet also regains MedImmune’s rights to any other bi-specific T-cell engager (BiTE) antibodies binding to antigens relevant for hematological cancers that had been reserved for MedImmune under the original agreement.

In March MedImmune returned the North American rights to develop and commercialize blinatumumab but retained an option to reacquire the right to commercialize the molecule in this region. By terminating the agreement, Micromet now controls global rights to develop and commercialize blinatumomab.

Micromet will pay an up-front fee as well as milestones related to development and royalties on North American net sales of blinatumomab. The original deal called for Micromet to receive development, filing, registration, and marketing success-based payments as well as royalties on MedImmune's North American sales of the product.

In June 2003, when the original deal was signed, blinatumomab was Micromet’s most advanced BiTE antibody. Since then the drug has advanced into a Phase II trial in acute lymphoblastic leukemia (ALL) and a Phase I study in non-Hodgkin's lymphoma. Micromet intends to initiate a late-stage trial in ALL next year. 

Blinatumomab targets the CD19 surface antigen, which is specific for B cells. The therapy has orphan drug designation for chronic lymphocytic leukemia and mantle cell lymphoma.

 

♦♦♦
Related News
Micromet Obtains $11.84M Up Front in Cancer R&D Deal with Sanofi-Aventis (Oct. 29, 2009)
Genzyme's Label-Expansion Efforts for ALL Therapy Receive Setback from the FDA (Oct. 7, 2009)
Micromet Nets $2M Milestone Payment from Nycomed with Filing of Clinical Trial Application (Apr. 2, 2009)
Bayer Gains Option to Preclinical Antibody from Micromet for $6M (Jan. 12, 2009)
Micromet Could Earn $167M in Alliance with Nycomed (May 24, 2007)

• Email
• Print
• Share
• More GEN News Highlights

Comment on this News:

Name:
Title:
Comment:
	HELP US FIGHT SPAMMING ROBOTS by answering the following simple question. It will verify you as a legitimate user wishing to post a comment. Thank you for your cooperation.

CAREER CENTER

WEBINARS

PODCASTS

MOST POPULAR